Does Z12.4 require prior authorization?

No, Z12.4 does not require prior authorization (medium confidence). Covered without prior authorization by at least one policy, though another does not cover it.

Backwork Sign up free

`Z12.4`, Encounter for screening for malignant neoplasm of cervix

ICD-10-CM

Prior Authorization

No Prior Auth Required

Covered without prior authorization by at least one policy, though another does not cover it (medium confidence)

Documentation Required

Laboratory validation/assay information when novel tests (FISH, methylation assays, mRNA assays, p16/Ki-67 dual stain) are used: method, probes/markers used, thresholds and interpretation criteria, and correlation with histology.
The document does not state explicit documentation requirements for coverage or billing.
Study-specific documentation referenced in the literature included cytology, hrHPV DNA status, mRNA test results, colposcopy findings, and histopathologic follow-up (e.g., CIN2+ endpoints) — but no payer-required documentation instructions are provided in the text.

Diagnostic Pap smears are considered medically necessary when Pap smear is accompanied by a diagnosis of a malignancy of the female genital tract (i.e., cervix, ovary, uterus, or vagina) — thus documentation must include the malignancy diagnosis.

Documentation must include a description of symptoms or a disease requiring diagnosis by a Pap smear when applicable (examples listed: Abnormal vaginal bleeding or discharge; Chronic cervicitis; Vaginal tumor).

Documentation must indicate if Pap smear is performed "following gynecological surgery for cancer."

Key Coverage Criteria

HPV DNA testing medically necessary: "Follow-up of women with low-grade squamous intra-epithelial lesions (LSIL) who have had negative colposcopy results within the past 2 years."
Li et al (2021): "This large routine-clinical-practice study confirmed the previously reported high sensitivity of hrHPV mRNA testing for the detection of high-grade cervical dysplasia and cervical cancers." (Aptima hrHPV mRNA testing co-testing data in HSIL cytology cases)
Zhang et al (2022): "The authors concluded that the AHPV assay is both specific and sensitive for detecting HSIL+ and may be suitable for use in primary cervical cancer screening in China. AHPV genotyping with reflex LBC triage may be a feasible triage strategy."
UpToDate (quoted in document): "RNA-based methods are not approved for primary HPV testing. However, they may be as effective as DNA-based methods in detecting cervical disease... Further studies evaluating RNA-based methods for primary HPV testing are needed."
Consistent with guidelines from the U.S. Preventive Services Task Force (USPSTF) and the American College of Obstetricians and Gynecologists (ACOG), Aetna considers annual cervical cancer screening with conventional or liquid-based Papanicolaou (Pap) smears a medically necessary preventive service for nonhysterectomized women age 21 years and older.
Pap screening is considered medically necessary beginning in adolescence in HIV-infected women. The ACOG guidelines on cervical cancer in adolescents (2010) recommend that adolescents with HIV have cervical cytology screening twice in the first year after diagnosis and annually thereafter.

3 Active Policies

CIGNA-A004, Preventive Care Services

CIGNA-0398, Transvaginal Ultrasound, Non-Obstetrical

AETNA-CPB-0443, Cervical Cancer Screening and Diagnosis

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about Z12.4 Sign up free

Z12.4, Encounter for screening for malignant neoplasm of cervix